The current clinical trial climate demands that sponsors find ways to reduce clinical trial complexity, drug development costs, and get more value from R&D budgets. Risk-based monitoring (RBM) allows organizations to target site monitoring activities for which risks can be best managed and deliver the greatest benefit to the study, and to become more effective and efficient in using resources, while increasing quality and patient safety. Participating TransCelerate Member Companies came together in 2012 to establish a model approach to high-quality RBM. To date, this effort has published a position paper on risk based monitoring, as well as several articles focused on sharing advancements, best practices and lessons learned from member companies adoption experience, all of which are publicly available. This short course, will define core concepts and main principles of the methodology, share key tools and discuss their use, share experiences and lessons learned, and address important questions about RBM and its implementation.
An additional registration fee is required for all preconference short courses.
Who should attend?
This short course is designed for professionals involved with clinical and data operations.
At the conclusion of this short course, participants should be able to:
- Define core concepts and main principles of the TransCelerate risk-based monitoring (RBM) methodology;
- Discuss the use of key tools in the RBM process;
- Identify common challenges with effective monitoring and discuss how they can be addressed through appropriate use of the RBM methodology.